Clinical Trials Logo

Clinical Trial Summary

Dextromethorphan Added on for Children With Chronic Irritability


Clinical Trial Description

Objectives: It is known that the etiology and mechanism of neuropsychiatric diseases may be related to nerve inflammation. It has been found that dextromethorphan (DM) is an active ingredient in cough-remedies, which can protect neurons in glial cell cultures in the rat brain from inflammatory substances. Although the mechanism of DM is still unknown, it may be related to the regulation of immune dysfunction. Therefore the purpose of this present study was to investigate the adjuvant treatment with DM in the children and adolescents with chronic irritability. Methods: This randomized double-blind clinical trial will evaluate 120 outpatients, aged between 7 and 17 years, with chronic irritability. The study subjects will be randomly assigned into one of the two groups: receiving routine medicine plus DM or routine medicine plus placebo for 8 weeks. Assessments comprising the parents' reported Mood Disorder Questionnaire (MDQ), Affective Reactivity Index (ARI), the Chinese version of the Child Behavior Checklist (CBCL-C) scale, the Swanson, Nolan and Pelham Questionnaire (SNAP-IV), the Sleep Disturbance Scale for Children (SDSC), Problematic smartphone use (PSU) and Checklist for Autism Spectrum Disorder-Chinese Version (CASD-C). Comparison will be done between groups at baseline and at 8 weeks before-and-after the treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05043805
Study type Interventional
Source Tri-Service General Hospital
Contact
Status Enrolling by invitation
Phase Phase 4
Start date May 9, 2021
Completion date June 30, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06133231 - Optimizing Research With Diverse Families N/A
Completed NCT03697837 - Digital Parent Training for Disruptive Behaviors in Children N/A
Completed NCT04776304 - Art Therapy qEEG Study for Service Members With a Traumatic Brain Injury and Posttraumatic Stress Symptoms N/A
Recruiting NCT01326663 - Divalproex Sodium for Mood Swings and Alcohol Use Following Head Injury. N/A
Completed NCT03592368 - Hostile Interpretation Bias Training to Treat Irritability N/A
Enrolling by invitation NCT04635618 - Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19 N/A
Completed NCT02507284 - Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease Phase 2
Completed NCT00627250 - Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability N/A
Recruiting NCT05388656 - Estrogen Variability and Irritability During the Menopause Transition Phase 4
Active, not recruiting NCT05260398 - Examining the Impacts on In-School Behaviors of In-Home Videogame Play N/A
Terminated NCT03863288 - Dose Response Relationship of Oxytocin on Irritability in Youths Phase 1/Phase 2
Completed NCT04715932 - Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN) Phase 2
Recruiting NCT05414708 - Art Therapy and Emotional Well Being in Military Populations With Posttraumatic Stress Symptoms N/A
Not yet recruiting NCT06020261 - Parent Management Training to Treat Irritability N/A
Recruiting NCT05528926 - RESist Against Irritability Superiority Trial N/A
Completed NCT05974241 - Irritability in Children With ADHD and Emotion Dysregulation Phase 4
Terminated NCT01675960 - Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children Phase 2
Recruiting NCT05930886 - Focus Groups in Ethnically and Racially Diverse Families